Skip to content
October 25, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Medical Research and Clinical Trials
  • Groundbreaking Cambridge Study Reveals Life-Saving Benefits of Ovarian Removal for Breast Cancer Patients with BRCA Gene Variants
  • Medical Research and Clinical Trials

Groundbreaking Cambridge Study Reveals Life-Saving Benefits of Ovarian Removal for Breast Cancer Patients with BRCA Gene Variants

Ammar Sabilarrohman September 29, 2026 17 minutes read
groundbreaking-cambridge-study-reveals-life-saving-benefits-of-ovarian-removal-for-breast-cancer-patients-with-brca-gene-variants

Cambridge, UK – [Insert Date] – In a significant advancement for women’s health, particularly for those battling breast cancer alongside a heightened genetic risk, new research from the University of Cambridge has definitively demonstrated that prophylactic surgery to remove the ovaries and fallopian tubes substantially reduces the risk of early death. This procedure, known as bilateral salpingo-oophorectomy (BSO), previously known to drastically cut ovarian cancer risk, has now been shown to offer broader, life-extending benefits without introducing serious long-term side effects for women carrying specific BRCA1 and BRCA2 genetic variants.

The study, the largest of its kind to date, published today in the prestigious journal The Lancet Oncology, provides crucial evidence for thousands of women making difficult decisions about their health. It addresses a long-standing concern within the medical community regarding the overall impact of early menopause induced by BSO, particularly for breast cancer survivors who often cannot receive hormone replacement therapy (HRT). The findings are expected to significantly influence clinical guidance and patient counselling worldwide.

Main Facts: A Paradigm Shift in Prophylactic Care

The core revelation of the Cambridge study is that bilateral salpingo-oophorectomy (BSO), a surgical procedure involving the removal of both ovaries and fallopian tubes, is associated with a substantial reduction in early mortality among women diagnosed with breast cancer who also carry pathogenic variants (PVs) in the BRCA1 and BRCA2 genes. This reduction in the risk of premature death encompasses not only cancer-related causes but also mortality from any other cause. Critically, the comprehensive analysis found no increased risk of adverse long-term health outcomes such as heart disease, stroke, or depression, which had been theoretical concerns due to the abrupt onset of menopause.

For decades, BSO has been offered as a vital risk-reduction strategy for BRCA1 and BRCA2 carriers, primarily to prevent ovarian cancer, a particularly aggressive and often late-diagnosed malignancy. While its efficacy in ovarian cancer prevention was well-established – an estimated 80% reduction in risk – the broader implications for overall survival, especially in the complex context of a prior breast cancer diagnosis, remained less clear. This new research, led by a team at the University of Cambridge in collaboration with NHS England’s National Disease Registration Service (NDRS), meticulously investigated these broader outcomes by leveraging extensive electronic health records and genetic testing data.

The study’s findings are particularly pertinent for women who have already faced a breast cancer diagnosis. These individuals often present unique challenges, as the estrogen-depleting effects of BSO can exacerbate menopausal symptoms, and the use of hormone replacement therapy (HRT) to mitigate these symptoms is frequently contraindicated due to their breast cancer history. The clear demonstration of a significant survival advantage, coupled with the absence of serious long-term side effects, offers profound reassurance and a compelling rationale for considering BSO as a truly life-saving intervention. The research underscores that the benefits extend beyond specific cancer prevention, positively impacting overall health trajectories for these high-risk women.

Chronology: From Genetic Discovery to Definitive Evidence

The journey to understanding the profound impact of BRCA gene variants and the role of prophylactic surgery is a testament to decades of scientific endeavour.

The Genesis of Genetic Understanding and Risk Assessment

The story begins in the mid-1990s with the groundbreaking discovery of the BRCA1 and BRCA2 genes. Scientists identified these genes as crucial tumour suppressors; when mutated (carrying a pathogenic variant), they significantly increase an individual’s lifetime risk of developing certain cancers, most notably breast and ovarian cancers. Women inheriting a BRCA1 variant face an estimated lifetime risk of up to 72% for breast cancer and up to 44% for ovarian cancer. For BRCA2 variant carriers, these risks are similarly elevated, estimated at up to 69% for breast cancer and up to 17% for ovarian cancer. These startling figures immediately prompted the medical community to explore aggressive risk-reduction strategies.

Among the earliest and most effective strategies identified was bilateral salpingo-oophorectomy (BSO). Given the insidious nature of ovarian cancer, which often presents with vague symptoms until advanced stages, surgical removal of the ovaries and fallopian tubes emerged as a powerful preventative measure. Guidelines were subsequently developed recommending BSO for BRCA1 carriers typically between the ages of 35 and 40, and for BRCA2 carriers between 40 and 45. This age-specific recommendation was designed to balance the accumulating cancer risk with the desire to preserve ovarian function for as long as safely possible, particularly for women who wished to complete childbearing. Early studies quickly confirmed the procedure’s efficacy in reducing ovarian cancer incidence by approximately 80%.

The Lingering "Uncertainty" and Ethical Dilemma

Despite the clear benefits in ovarian cancer prevention, a significant "question mark" persisted regarding the overall health impact of BSO, especially for women with a prior history of breast cancer. The abrupt cessation of ovarian hormone production following BSO plunges women into surgical menopause, which can be more severe than natural menopause. Concerns arose about potential unintended long-term consequences, including an increased risk of cardiovascular disease, osteoporosis, and neurocognitive issues like depression, all linked to estrogen deprivation. For breast cancer survivors, these concerns were amplified, as many are advised against or cannot receive hormone replacement therapy (HRT) due to the potential for stimulating breast cancer recurrence, leaving them to manage menopausal symptoms without pharmaceutical aid. The comprehensive impact of BSO on overall survival, factoring in these potential adverse effects, remained largely uncertain.

Traditionally, the "gold standard" for evaluating medical interventions is the randomised controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the intervention (BSO) or a control (no BSO), allowing researchers to isolate the intervention’s effects. However, for women carrying BRCA1 and BRCA2 variants, conducting an RCT for BSO would be ethically unconscionable. Randomly assigning some high-risk women to not receive a procedure known to dramatically reduce the risk of a deadly cancer would deliberately place them at a substantially greater risk of developing ovarian cancer, violating the fundamental principle of "do no harm." This ethical impasse meant that direct, high-level evidence on the overall survival benefits and comprehensive safety profile of BSO had been elusive.

The Innovative Research Approach: Unlocking NHS Data

To circumvent this ethical dilemma, the research team at the University of Cambridge, spearheaded by first author Hend Hassan and senior author Professor Antonis Antoniou, devised an ingenious methodological solution. They turned to the vast, rich, and meticulously curated electronic health records and genetic testing laboratory data collected by the National Disease Registration Service (NDRS) in NHS England. This "real-world" data, encompassing thousands of patient journeys, offered a unique opportunity to retrospectively compare the long-term outcomes of BRCA1 and BRCA2 pathogenic variant carriers who had undergone BSO against those who had not, all within a natural clinical setting.

This innovative approach allowed the researchers to effectively mimic the comparative power of an RCT without exposing any individual to undue risk. By analysing anonymised data from a large cohort of women, they could track health trajectories, incidence of subsequent cancers, and overall mortality rates over many years. This pioneering methodology, leveraging the "power of exceptional NHS datasets," enabled the first large-scale study of its kind to provide definitive answers to questions that had long troubled both patients and clinicians, marking a crucial turning point in understanding the holistic impact of BSO.

Supporting Data: Unveiling the Unambiguous Benefits and Persistent Disparities

The Cambridge study’s meticulous analysis of real-world patient data yielded compelling evidence of BSO’s life-saving potential, while also highlighting concerning disparities in its uptake.

Study Cohort and Surgical Uptake

The collaborative effort between the University of Cambridge and the National Disease Registration Service (NDRS) at NHS England allowed for the identification of a substantial cohort. The team identified a total of 3,400 women who carried either a BRCA1 or BRCA2 cancer-causing variant and had also been diagnosed with breast cancer. This cohort was evenly split, with approximately 1,700 women for each variant. Within this group, a significant proportion had undergone BSO surgery: around 850 of the BRCA1 carriers and approximately 1,000 of the BRCA2 carriers had opted for the procedure. This robust sample size provided ample statistical power to draw meaningful conclusions about long-term outcomes.

Dramatic Reduction in Mortality and Secondary Cancers

The most striking finding was the profound impact of BSO on overall survival. Women who underwent BSO were found to be around half as likely to die from cancer or any other cause over the follow-up period, which had a median duration of 5.5 years. This significant reduction in early death underscores the broad protective effect of the surgery.

Further granular analysis revealed differences between the two gene variants:

  • BRCA2 Carriers: Experienced a 56% reduction in early death risk. This greater protective effect in BRCA2 carriers is particularly noteworthy and warrants further investigation into underlying biological mechanisms.
  • BRCA1 Carriers: Saw a 38% reduction in early death risk. While slightly lower than for BRCA2, this remains a substantial and clinically significant benefit.

Beyond overall mortality, the study also demonstrated a critical reduction in the risk of developing a second primary cancer. Women who underwent BSO were approximately 40% less likely to be diagnosed with another cancer. This finding suggests that the hormonal changes induced by BSO may have a systemic protective effect, potentially influencing the development of other estrogen-sensitive cancers or modulating cellular pathways involved in carcinogenesis. While the researchers acknowledge that it is "impossible to say with 100% certainty that BSO causes this reduction in risk," they assert that the body of evidence points "strongly towards this conclusion," given the robust statistical associations observed.

Reassuring Absence of Adverse Long-Term Effects

A crucial aspect of the study was its investigation into the potential long-term adverse effects of BSO, particularly in the context of early menopause. Previous studies in the general population had, at times, suggested an association between surgical removal of ovaries and an increased risk of conditions like heart disease, stroke, and depression. However, for this specific high-risk cohort of BRCA1 and BRCA2 carriers with a history of breast cancer, the Cambridge team found no such link. This is a profoundly reassuring discovery for both patients and clinicians, effectively allaying fears that the benefits of cancer prevention might be offset by other serious health complications. The finding suggests that the protective effects of BSO against cancer progression and mortality outweigh, or perhaps even mitigate, the potential risks associated with estrogen deprivation in this specific population.

Persistent Disparities in BSO Uptake

Despite the clear and unambiguous benefits, the study uncovered concerning disparities in who receives BSO. The data revealed significant inequalities based on ethnicity and socioeconomic status:

  • Racial Disparity: Black and Asian women were approximately half as likely to undergo BSO compared to white women. This stark difference highlights potential systemic barriers, including lack of awareness, cultural factors influencing decision-making, communication gaps, or unequal access to specialised genetic counselling and surgical services.
  • Socioeconomic Disparity: Women residing in less deprived areas were more likely to have undergone BSO compared to those in the most-deprived categories. This finding suggests that socioeconomic factors, such as access to information, healthcare navigation support, or the ability to take time off for appointments and recovery, may play a critical role in uptake.

These disparities underscore an urgent need for targeted interventions to ensure equitable access to this life-saving procedure across all eligible populations. Understanding the root causes of these inequalities will be paramount to addressing them effectively.

Official Responses: Endorsement, Empowerment, and Future Vision

The findings of this landmark study have been met with strong endorsements from the research team, funding bodies, and the broader medical community, highlighting both the immediate clinical impact and the potential for future advancements.

Voices from the Research Team

Hend Hassan, the study’s first author and a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, articulated the profound implications of the findings for patient reassurance. "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes," Hassan explained. "Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."

Hassan also voiced concern over the identified disparities in BSO uptake: "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women." This statement underscores a dual responsibility: to disseminate the positive findings and to actively work towards equitable access.

Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, emphasised the practical utility of the research for clinical practice. "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation," Professor Antoniou stated. This highlights the study’s role in empowering patients with robust, evidence-based information.

Professor Antoniou, who also serves as Director of the Cancer Data-Driven Detection programme, further lauded the innovative methodological approach: "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." This recognition points to the vast potential of leveraging comprehensive national health data for future medical breakthroughs, especially in scenarios where traditional research methods are ethically constrained.

Support from Funding and Institutional Partners

The critical research was made possible through the generous support of key funding bodies. Cancer Research UK provided the primary funding, underscoring their commitment to advancing cancer prevention and treatment. Additional support was received from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, further solidifying the collaborative spirit driving medical innovation in the UK.

The broader institutional context of this research is also noteworthy. The University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for a new Cambridge Cancer Research Hospital. This ambitious project, a partnership with Cambridge University Hospitals NHS Foundation Trust, aims to transform cancer diagnosis and treatment for patients across the East of England and beyond. The impactful research emerging from Cambridge, such as this BSO study, exemplifies the kind of life-changing discoveries that such a dedicated facility will foster, promising to benefit cancer patients nationally and internationally.

Implications: Reshaping Clinical Guidelines, Addressing Inequalities, and Paving Future Research

The Cambridge study on BSO for BRCA1/2 carriers with breast cancer is not merely an academic exercise; its findings carry profound and far-reaching implications across clinical practice, public health policy, and future research directions.

Reshaping Clinical Practice and Patient Counselling

The most immediate and significant implication of this study is its power to strengthen and refine clinical guidelines for the management of BRCA1 and BRCA2 pathogenic variant carriers, particularly those with a history of breast cancer. For years, the decision regarding BSO in this specific population was often fraught with apprehension due to the unknown long-term consequences of early menopause without HRT. This research now provides unequivocal evidence of a substantial survival benefit and the absence of serious adverse effects, effectively removing a major barrier to informed decision-making.

Clinicians, including oncologists, genetic counsellors, and gynaecologists, can now counsel their patients with greater confidence, presenting BSO not only as an ovarian cancer prevention strategy but as a procedure that significantly reduces the overall risk of early death and subsequent cancers. This clarity is invaluable for patients grappling with complex choices, allowing them to weigh the benefits against the discomforts of surgical menopause with a more complete understanding of the profound positive impact on their longevity and quality of life. The study empowers both providers and patients to engage in more confident and proactive discussions about this life-saving intervention.

Addressing Health Inequalities in BSO Uptake

The study’s uncovering of significant disparities in BSO uptake among different racial and socioeconomic groups is a critical finding that demands urgent attention. The fact that Black and Asian women, as well as those from more deprived areas, are substantially less likely to undergo a procedure offering such clear benefits highlights systemic inequities within healthcare access and delivery.

Addressing these disparities is paramount to ensuring equitable health outcomes. This will necessitate a multi-faceted approach:

  • Further Research: Delving deeper into the specific reasons behind these disparities is crucial. This includes exploring factors such as awareness levels within different communities, cultural or religious beliefs influencing medical decisions, communication styles of healthcare providers, access to specialist genetic counselling services, financial burdens associated with surgery and recovery, and language barriers.
  • Targeted Outreach and Education: Developing culturally sensitive educational materials and outreach programs tailored to underserved communities can help raise awareness of BRCA risks and the benefits of BSO.
  • Improved Access to Care: Ensuring equitable access to genetic testing, counselling, and surgical facilities, regardless of geographical location or socioeconomic status, is vital. This might involve mobile clinics, community-based navigators, or policies aimed at reducing out-of-pocket costs.
  • Provider Training: Training healthcare professionals on implicit biases and culturally competent communication can improve patient-provider interactions and ensure that all eligible women receive comprehensive and unbiased information.

By actively addressing these inequalities, the healthcare system can ensure that the life-saving benefits of BSO are accessible to all women at risk, irrespective of their background.

Validation of Innovative Research Methodology

The Cambridge study stands as a powerful testament to the utility and impact of leveraging large-scale, real-world data from electronic health records and national registries. In situations where traditional randomised controlled trials are ethically impossible, such as with BSO for BRCA carriers, this "data-driven detection" approach offers a robust and reliable alternative for generating high-quality evidence.

This methodological success has broader implications for medical research. It demonstrates that combining clinical expertise with advanced data analytics can unlock answers to complex clinical questions, accelerate the translation of research into practice, and inform healthcare policy effectively. It underscores the value of investing in comprehensive national health datasets and the infrastructure required to analyse them, paving the way for similar impactful studies in other challenging medical scenarios.

Future Directions in Research and Clinical Practice

While this study provides definitive answers, it also opens new avenues for future research:

  • Mechanisms of Broader Benefit: Further investigation into the precise mechanisms by which BSO reduces overall mortality and the risk of secondary cancers beyond ovarian cancer is warranted. Does it alter the hormonal milieu in a way that impacts other estrogen-sensitive cancers or systemic inflammation?
  • Long-Term Monitoring: Continued, ultra-long-term follow-up of BSO patients will be important to confirm the sustained absence of adverse effects and to track very rare long-term complications, if any.
  • Personalised Risk Assessment: While age guidelines exist, future research could explore more personalised approaches to timing BSO based on individual risk factors, genetic profiles, and lifestyle.
  • Impact on Quality of Life: While the study found no link to depression, further qualitative and quantitative research into the broader impact of surgical menopause on quality of life, sexual health, and cognitive function for these women could provide valuable insights for comprehensive supportive care.

In conclusion, the Cambridge study represents a monumental leap forward in the care of women at high genetic risk for cancer. By unequivocally demonstrating the profound survival benefits of bilateral salpingo-oophorectomy, it empowers patients and clinicians alike with clarity and confidence, while simultaneously calling for a concerted effort to dismantle the barriers that prevent equitable access to this life-saving procedure. The findings are a beacon of hope, promising longer, healthier lives for thousands of women worldwide.

About the Author

Ammar Sabilarrohman

Author

View All Posts

Post navigation

Previous: Precision in Plastic Surgery: New AI Model Predicts Blood Loss with 94% Accuracy in Large-Volume Liposuction
Next: Next Post

Related Stories

unraveling-the-colorectal-cancer-paradox-msk-researchers-discover-dual-roles-of-immune-cells-paving-way-for-new-therapies
  • Medical Research and Clinical Trials

Unraveling the Colorectal Cancer Paradox: MSK Researchers Discover Dual Roles of Immune Cells, Paving Way for New Therapies

Azzam Bilal Chamdy October 25, 2026
new-evidence-shows-depression-linked-to-circadian-rhythm
  • Medical Research and Clinical Trials

New evidence shows depression linked to circadian rhythm

Nana Muazin October 25, 2026
a-pivotal-discovery-unlocking-the-mystery-of-colorectal-cancers-spread-to-the-liver
  • Medical Research and Clinical Trials

A Pivotal Discovery: Unlocking the Mystery of Colorectal Cancer’s Spread to the Liver

Nana October 24, 2026

Recent Posts

  • Unraveling the Colorectal Cancer Paradox: MSK Researchers Discover Dual Roles of Immune Cells, Paving Way for New Therapies
  • New evidence shows depression linked to circadian rhythm
  • A Storm of Resilience: Brenja’s Journey Through Triple-Negative Breast Cancer
  • Bridging the Gap: METAvivor’s 2026 Legislative Strategy and the Push for Metastatic Breast Cancer Research Reform
  • New Hope for ‘Chemo Brain’: Oxaloacetate Supplement Shows Promise in Reversing Cognitive Decline for Breast Cancer Survivors

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

unraveling-the-colorectal-cancer-paradox-msk-researchers-discover-dual-roles-of-immune-cells-paving-way-for-new-therapies
  • Medical Research and Clinical Trials

Unraveling the Colorectal Cancer Paradox: MSK Researchers Discover Dual Roles of Immune Cells, Paving Way for New Therapies

Azzam Bilal Chamdy October 25, 2026
new-evidence-shows-depression-linked-to-circadian-rhythm
  • Medical Research and Clinical Trials

New evidence shows depression linked to circadian rhythm

Nana Muazin October 25, 2026
a-storm-of-resilience-brenjas-journey-through-triple-negative-breast-cancer
  • Patient Advocacy and Support

A Storm of Resilience: Brenja’s Journey Through Triple-Negative Breast Cancer

Azzam Bilal Chamdy October 25, 2026
bridging-the-gap-metavivors-2026-legislative-strategy-and-the-push-for-metastatic-breast-cancer-research-reform
  • Patient Advocacy and Support

Bridging the Gap: METAvivor’s 2026 Legislative Strategy and the Push for Metastatic Breast Cancer Research Reform

Dwi Wanna October 25, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.